HCM (HUTCHMED (China)) Total Liabilities : $508.9 Mil (As of Jun. 2024)

View and export this data going back to 2016. Start your Free Trial

What is HUTCHMED (China) Total Liabilities?

HUTCHMED (China)'s Total Liabilities for the quarter that ended in Jun. 2024 was $508.9 Mil.

HUTCHMED (China)'s quarterly Total Liabilities increased from Jun. 2023 ($497.48 Mil) to Dec. 2023 ($536.39 Mil) but then declined from Dec. 2023 ($536.39 Mil) to Jun. 2024 ($508.85 Mil).

HUTCHMED (China)'s annual Total Liabilities increased from Dec. 2021 ($333.15 Mil) to Dec. 2022 ($392.58 Mil) and increased from Dec. 2022 ($392.58 Mil) to Dec. 2023 ($536.39 Mil).

HUTCHMED (China) Total Liabilities Historical Data

The historical data trend for HUTCHMED (China)'s Total Liabilities can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

HUTCHMED (China) Total Liabilities Chart

HUTCHMED (China) Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Total Liabilities

Get a 7-Day Free Trial

152.22

205.17

333.15

392.58

536.39

HUTCHMED (China) Semi-Annual Data
	Dec14	Jun15	Dec15	Jun16	Dec16	Jun17	Dec17	Jun18	Dec18	Jun19	Dec19	Jun20	Dec20	Jun21	Dec21	Jun22	Dec22	Jun23	Dec23	Jun24
Total Liabilities	Get a 7-Day Free Trial															342.48	392.58	497.48	536.39	508.85

HUTCHMED (China) Total Liabilities Calculation

Total Liabilities are the liabilities that the company has to pay others. It is a part of the balance sheet of a company that shareholders do not own, and would be obligated to pay back if the company liquidated.

HUTCHMED (China)'s Total Liabilities for the fiscal year that ended in Dec. 2023 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	403.027	+	(51.049	+	82.31
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	536.4

Total Liabilities	=	Total Assets (A: Dec. 2023 )	-	Total Equity (A: Dec. 2023 )
	=	1279.773	-	743.387
	=	536.4

HUTCHMED (China)'s Total Liabilities for the quarter that ended in Jun. 2024 is calculated as

Total Liabilities	=	Total Current Liabilities	+	Total Noncurrent Liabilities
	=	Total Current Liabilities	+	(Long-Term Debt & Capital Lease Obligation	+	Other Long-Term Liabilities
	=	373.288	+	(55.632	+	79.93
	+	NonCurrent Deferred Liabilities	+	PensionAndRetirementBenefit)
	+	0	+	0)
	=	508.9

Total Liabilities	=	Total Assets (Q: Jun. 2024 )	-	Total Equity (Q: Jun. 2024 )
	=	1260.868	-	752.018
	=	508.9

HUTCHMED (China) Total Liabilities Related Terms

Thank you for viewing the detailed overview of HUTCHMED (China)'s Total Liabilities provided by GuruFocus.com. Please click on the following links to see related term pages.

HUTCHMED (China) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » HUTCHMED (China) Ltd (NAS:HCM) » Definitions » Total Liabilities

Comparable Companies

Traded in Other Exchanges

00013:Hong Kong 0J7G:UK HCM.GB:UK HCM:UK H7T1:Germany H7T1:Germany H7T2:Germany

Address

2 Queen's Road Central, 48th Floor, Cheung Kong Center, Hong Kong, HKG

Website

https://www.hutch-med.com

HUTCHMED (China) Ltd is an innovative biopharmaceutical company engaged in the discovery, global development, and commercialization of targeted therapies and immunotherapies for the treatment of cancer and immunological diseases. The company has a portfolio of several cancer drug candidates currently in clinical studies around the world and extensive commercial infrastructure in its home market of China. The company operates in two reportable segments Oncology/Immunology, and Other Ventures.